<DOC>
	<DOCNO>NCT01318460</DOCNO>
	<brief_summary>The present pilot study aim investigate effectiveness preoperative infusion levosimendan patient impaired leave ventricular function undergo coronary artery bypass grafting .</brief_summary>
	<brief_title>Prophylactic Administration Levosimendan Patients Undergoing Coronary Surgery</brief_title>
	<detailed_description>Myocardial revascularization patient impaired leave ventricular function remain serious problem cardiac surgery . Despite recent development use new surgical technique ( mini-extracorporeal circulation , pump surgery ) perioperative morbidity mortality relatively high . Therapeutic solution use inotropic drug , adrenergic agonist phosphodiesterase inhibitor , offer important improvement hemodynamic status patient , considerably decrease mortality . These drug owe positive inotropic action increase intracellular calcium thereafter improve myocardial function . Levosimendan ( SIMDAX ) new calcium sensitizer increase myocardial contractility without particular promotion intracellular calcium accumulation . Contemporary experimental clinical data demonstrate effectiveness drug reduction surgical mortality patient low leave ventricular ejection fraction ( LVEF ) undergo coronary artery bypass grafting ( CABG ) . This original prospective randomize control study focus preoperative use drug patient impaired leave ventricular function associate high operative risk ( i.e . EuroSCORE ) . Perioperative myocardial stun particularly evident cohort patient . Prophylactic administration levosimendan day operation could translate improved myocardial performance intraoperatively early postoperative period .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<criteria>coronary artery disease warrant myocardial revascularization coronary artery bypass graft accord current guideline age &lt; 79 year old leave ventricular ejection fraction &lt; = 40 % informed patient 's consent age &lt; 18 year old emergency surgery medical history acute myocardial infarction ST elevation ( STEMI ) less 14 day old severe comorbidity increase perioperative risk ( i.e . neoplasia , rheumatoid arthritis , chronic obstructive pulmonary disease ) need valvular replacement surgery redo surgery serum creatinine &gt; 2 mg/dl history malignant cardiac arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>coronary artery disease</keyword>
	<keyword>levosimendan</keyword>
	<keyword>coronary artery bypass grafting</keyword>
	<keyword>cardiac surgery</keyword>
</DOC>